A new method for the reliable identification of localized variations in DNA by detection of associated diagnostic products with matrix-assisted laser desorption ionization time-of-flight mass spectrometry is described. The diagnostic products are generated by the primer oligo base extension (PROBE) reaction, which requires a single detection primer complementary to a region downstream of a target strand's variable site. On addition of a polymerase, three dNTPs, and the fourth nucleotide in dideoxy form, the primer is extended through the mutation region until the first ddNTP is incorporated; the mass of the extension products determines the composition of the variable site. Tests for five cystic fibrosis mutations, including two exon 11 sites measured in a biplex reaction, and for differentiating between three common alleles of the poly(T) tract at the intron 8 splice acceptor site of the CFTR gene are presented. All experimental steps required for PROBE are amenable to the high degree of automation desirable for a high-throughput diagnostic setting. Furthermore, it requires no fluorescent, chemiluminescent, or radioactive labeling; the mass signals measured offer a far more analytically definitive signal, leading in all cases to high-quality unambiguous and easily interpreted results.
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Subsequent to the cloning of many human genes and the concomitant recognition of mutations related to monogenic diseases or cancers will come increased demand for DNA diagnostics. For many disorders, e.g., those caused by cystic fibrosis transmembrane regulator (CFTR), 3 p53, or BRCA1 mutations, the genetic cause exhibits a high degree of allelic diversity. DNA sequences associated with disease may differ from corresponding normal sequences, mostly in single or in a few nucleotide positions. For example, Ͼ580 mutations in the CFTR gene have been described [1] ; screening for all of these delocalized mutations would require substantial sequencing at a substantial waste of time and money. Therefore, it is necessary to screen for both predominant and less common mutations. The recommended number of screened mutations depends also on the patients' ethnic background [2] ; e.g., 17 mutations must be screened for in the Scottish population to achieve ϳ80% diagnostic detection limits for cystic fibrosis (CF) [3] . For the German population, however, use of mutation detection assays able to detect 50 different mutations would result in only 70% diagnostic detection limits for the same autosomal recessive disease [4] . In the past several years methods have been developed with a potentially high degree of multiplexing in efforts to increase sample-throughput capabilities: reverse dot blots [5] , amplification refractory mutation systems [6] , sequencing by hybridization [7] , oligo ligation assay [8] , genetic bit analysis [9] , and solid-phase minisequencing [10 -12] . Some of the allele-specific tests [5] [6] [7] require high hybridization/annealing stringency for high-quality results; this can complicate multiplexing because the mutually independent temperature and buffer conditions as optimized for one allele may be deoptimized for another, potentially leading to unrecognized false-positive or falsenegative results.
Mass spectrometry (MS) is another separation and detection scheme that has been used for decades in the identification and structural determination of small biomolecules such as metabolites. The introduction of the gentle ionization technique matrix-assisted laser desorption (MALDI) [13] [14] [15] and electrospray ionization [16] have made it possible to extend the inherent analytical advantages of MS to the analysis of far larger biomolecules. With the former, analyte molecules are cocrystallized with a matrix having a strong absorbance at the wavelength of a pulsed laser and ionized by proton transfer. With the latter, an aqueous solution containing analyte is passed through a highly charged (ϳ2 kV) needle; the resulting highly charged droplets desolvate until multiply charged ions are emitted.
Although sizing and partial sequence analysis of recombinant and extracted proteins by MS are now in most cases routine [17] , progress with DNA has been slower. Its labile phosphodiester backbone and the tendency for base cleavage from deoxyribose makes intact volatilization of larger strands challenging [18] . Furthermore, the affinity of the negatively charged backbone phosphate groups for nonvolatile cation (Na ϩ ,K ϩ ) adduction spreads the molecular ion signal into several peaks, decreasing the signal-to-noise ratio and molecular mass measurement accuracy with instrumentation of insufficient resolving power to differentiate adduct from molecular ion signal. However, after careful sample preparation [19, 20] and use of low-energy-source conditions, signal from DNA up to a 500-mer has been observed with MALDI [21] . Meanwhile, the potential of MS in diagnostics of clinical samples through amplified DNA has been demonstrated [19, 22, 23] .
We present a new method of mutation detection combining primer oligo base extension (PROBE) with mass measurement by MALDI coupled with time-of-flight (TOF) MS. PROBE is a solid-phase method principally similar to minisequencing [10 -12] , and both can be performed without excessive attention to stringency. A single mutation detection primer is annealed to a target downstream of a mutation region and on addition of a polymerase, three dNTPs, and one ddNTP, undergoes an oligonucleotide extension through the mutation region. Product lengths are determined directly from their molecular mass (M r ) so that labeling the DNA is unnecessary; the high duty cycle of TOF-MS (single-shot spectrum acquisition Ͻ1 s) makes it far more amenable to highthroughput screening programs than fluorescent or radioactive methods, which require slow electrophoretic separation or hybridization procedures. The model system used here comprises three clinically relevant CFTR gene regions.
Materials and Methods genomic dna
Genomic DNA was obtained from healthy individuals, individuals homozygous for the ⌬F508 mutation, and individuals compound-heterozygous or simple-heterozygous for other mutations leading to CF. All wild-type and mutant alleles in the exons tested thus far have been confirmed by standard Sanger sequencing.
pcr amplification
Oligonucleotides were synthesized in-house on a Perseptive Expedite DNA synthesizer using standard ␤-cyanoethanol phosphoamidite chemistry [24] . PCR primers, biotinylated (-bio) as indicated, were delineated from the CFTR intron sequences [25] . Exon 
purification of pcr products
Amplification products were purified using Qiagen's PCR purification kit 28106 according to the manufacturer's instructions; purified products were eluted with 50 L of TE buffer (10 mmol/L Tris, 1 mmol/L EDTA, pH 7.5). denaturation and precipitation of extended primer
The extended primer was denatured from the template strand after addition of 50 L of 50 mmol/L ammonium hydroxide in 100 mL/L dimethyl sulfoxide solution by heating at 80°C for 10 min in a hybridization oven. For precipitation, 5 L of 3 mol/L ammonium acetate (pH 6.5), 0.5 L of glycogen (10 g/L, cat. no. G1765; Sigma Chemical Co., St. Louis, MO), and 110 L of absolute ethanol were added to the supernatant and incubated for 1 h at room temperature. After centrifugation at 13 000g for 10 min, the pellet was washed in ethanol:water (70:30, by vol) and resuspended in 1 L of 18 M⍀/cm H 2 O. Considering that both the known amount of PCR products used and the hybridization/precipitation efficiency were high, it was estimated that ϳ3 pmol of diagnostic product was available for MS analysis. Results Figure 1 presents a schematic overview of the PROBE experiments for potential sequence variations in exons 10 and 11 and intron 8 of the CFTR gene. In exon 10, for instance, the sense strand of the PCR product served as template; the nucleotides by which the primer was extended are depicted in bold letters. Two specific termination reactions (ddTTP and ddCTP, Fig. 1, a and b) were performed to investigate known mutations at the codons 506, 507, and 508. Figure 2 , a and b, shows mass spectra of PROBE reaction products generated from a negative control, i.e., a sample that is homozygous-normal at each of the codons 506, 507, and 508. In the ddT and ddC reactions, the 7288.8-Da 24-mer primer is converted entirely to products consistent with the addition of 5 (8842.8 Da, Fig. 2a ) and 14 (11 609.7 Da, Fig. 2b ) bases, respectively; the result in Fig. 2a is consistent with not only wild-type, but also a genotype homo-or heterozygous for I506S and ⌬I507. To resolve this ambiguity, these are readily distinguished on consideration of the ddC reaction, in which wild-type, I506S, and ⌬I507 alleles yield products of dramatically different mass (11 609 vs 9468 and 10 653 Da, respectively). Thus only by consideration of both the ddT and ddC reactions can this genotype be verified as homozygousnormal.
MS
The split peaks in Fig. 2c (ddT) indicate a heterozygous genotype in which two diagnostic products result from a single detection primer; those primers that anneal to allele 1 (Table 1) are again extended by 5 bases (8839.5 Da), whereas those that anneal to allele 2 are extended by only 2 bases (7885.8 Da); the latter can only be from ⌬F508. Again, consideration of the ddC reaction (Fig. 2d) for this patient is needed for an unambiguous analysis; the 11 606-Da fragment can be generated only from a wildtype, while the 10 653-Da product confirms the presence of ⌬F508. Further genotype assignment for patients homozygous for ⌬F508 (Fig. 2, e and f) , compound heterozygote ⌬I507/⌬F508 (Fig. 2, g and h) , and heterozygote for I506S (Fig. 2, i and k) are equally definitive, even though the two molecular species of the peak in Fig. 2h (⌬m ϭ 9 Da) are not resolved.
PROBE was also used for simultaneous (biplex) detection of the CFTR gene exon 11 G542X and R553X mutations in two patients. As seen in Fig. 1c , the ddT reaction alone is sufficient to differentiate between mutant and wild-type states at each codon. For the first sample, the codon 553 primer is converted only to a 9277.9-Da product consistent with wild-type; the codon 542 primer is converted to a pair of peaks at 9952.1 and 7371.2 Da. Thus this sample is homozygous wild-type at codon 553 and heterozygous for the codon 542 mutation. Similar analysis for the sample in Fig. 3b shows it to be homozygous wild-type at codon 542 and heterozygous for the codon 553 mutation (Table 1, Fig. 1c) . Although MALDI-TOF MS to date is not considered a quantitative analytical method Clinical Chemistry 43, No. 7, 1997 for DNA analysis, the relative peak heights of the reaction products corresponding to the heterozygous position are in both of the Fig. 3 samples about one-half of those corresponding to the homozygous position. These are the peaks with the masses 7371.2 and 9952.1 Da (heterozygous site for codon 542, Fig. 3a ) compared with the peak with the mass 9277.9 Da (homozygous wild-type site for codon 553, Fig. 3a ) and the peaks with the masses 6149.4 Da and 9275.4 Da (heterozygous site for codon 553, Fig.  3b ) compared with the peak with the mass 9940.0 Da (homozygous wild-type site for codon 542, Fig. 3b) .
As a third example we tested the efficiency of the method in determining the number of thymidines in the intron 8 splice acceptor site; the number of thymidines is relevant to the degree of exon 9 skipping during maturation of the CFTR mRNA [27] . Each of the three common alleles (T5, T7, T9) in Fig. 1d are represented in samples from two different patients. M r (exp) values from the first (Fig. 4a) were consistent with a T5/T9 heterozygote genotype, while those from the second (Fig. 4b) were consistent with T7/T9. For both, measured masses were in good agreement with M r (calc) values of 6890.6 (T5), 7515.0 (T7), and 8139.4 Da (T9).
The effect of extension by modified [28] , rather than by normal, purines is demonstrated on comparison of Fig. 4 , b and c. The extension reaction of the template heterozygous for the T7/T9 alleles was performed with (Fig. 4b) and without (Fig. 4c) N-7 deazaadenine. In the latter, signal from fragmented (i.e., MALDI-induced depurination) extension products is far more intense, decreasing the total signal-to-noise ratio of molecular ions by distributing signal into several peaks.
Calculated vs observed M r values are listed in Table 1 . The accuracy of M r (exp) from all experiments ranged a, exon 10, ddTTP termination; b, exon 10, ddCTP termination; c, exon 11 biplex reaction, ddTTP termination; d, intron 8 -exon 9 splice acceptor site, ddCTP termination. Bold, nucleotides by which detection primer is extended. Fig. 2 . MALDI-TOF mass spectra of PROBE products for detection of CFTR exon 10 mutations in five patients.
For each pair of spectra, ddTTP and ddCTP termination are shown at left and right, respectively. a and b, homozygous wild-type; c and d, heterozygote wild-type/⌬F508; e and f, homozygous ⌬F508; g and h, compound heterozygote ⌬I507/⌬F508; i and k, heterozygote wild-type/I506S. Asterisks, depurination peaks. from Ϫ5.6 to ϩ10.5, in all cases within 0.1% of M r (calc). Thus, a definitive interpretation of the results is allowed in each case, because the mass difference of the diagnostic products of the PROBE method specific for wild-type or mutation is at least one nucleotide (average mass 309 Da).
Discussion
The majority of molecular defects causing genetic diseases and polymorphisms associated with some disorders are single-nucleotide substitutions or small deletions/insertions that lead to alteration or loss of function of the gene products. The distribution of these defects is often widespread in one gene with some predominant and many rare mutations; in many cases the strategy to obtain acceptable diagnostic detection limits (Ͼ80%) must include analysis of several such mutations [3, 29] . This may be prohibitively time-consuming, especially if different methods are needed to detect the various mutations.
For high-quality DNA diagnostics, sequencing is the ideal analytical procedure in terms of detection limits and specificity; however, with current methods it remains too cumbersome for routine use in high-volume clinical screening programs. The PROBE assay in principle gives the same information for known mutations as obtained by diagnostic sequencing, albeit with far less effort. A mutation detection primer is elongated with three deoxynucleotides and terminated by the dideoxynucleotide not present in the deoxy form. Thus in all tests singlesequencing ladder molecules specific to either wild-type or mutant alleles are obtained. The solid-phase minisequencing procedure [10 -12] , in which a diagnostic primer is extended by a single labeled base, is a related method that has been successfully utilized for detection of alterations in a variety of genes. Initially, radioactive nucleotides were used, and the incorporated radioactivity was measured [10] ; subsequently, multiplexed formats were achieved by using primers of different length and fluorescent dideoxynucleotides, followed by electrophoretic separation of the products [12] . Minisequencing as described thus far is not applicable to loci in which several adjacent mutations are possible, such as codons 506 -508 in exon 10 of the CFTR gene, or to cases where the number of identical adjacent bases is relevant, such as the CFTR intron 8 poly(T) tract. The PROBE assay clearly differentiates known codon 506 -508 mutations and quantitates exactly the number of identical bases in a sequence of consecutive T nucleotides, demonstrating the resolution of PROBE and MS detection. The MS evaluation of PROBE analytes does not require labeled DNA; the mass of the product itself provides a far more analytically specific signal than a base-specific color found with fluorescent detection, the product size of which can be estimated only by comparing its relative electrophoretic mobility with that of an internal calibrator. Using external calibration, the maximum deviation of M r (exp) from M r (calc) was 0.09% (wild-type ⌬F508 ddCTP termination: expected 11 604.6 Da, observed 11 615.1 Da). Although the resolution of the reflectron TOF utilized in this study is too low for differentiation of detection products with very similar masses (i.e., A vs T, ⌬m 9.0 Da, ddC termination reaction of ⌬I507 vs ⌬F508, Fig. 2h) , the recent reintroduction of delayed ion extraction instrumentation has enabled resolution improvements of an order of magnitude on oligonucleotides in this mass range [30] .
In conclusion, the PROBE assay with the evaluation of its products by MS is a promising replacement for conventional mutation detection systems; diagnostic product masses represent a highly definitive and unambiguous signal compared with a relative electrophoretic mobility. The MALDI-TOF technology has now been developed to a state where it can be applied to DNA diagnostics, and current efforts on improved sample preparation, automation of laser scanning and data collection, and more extensive multiplexing are directed at making this the future method of choice for high-throughput, analytically robust DNA diagnostics.
